文献速递临床试验与 GCP

左卡尼汀补充对重症监护病房(ICU)脓毒症患者炎症因子、氧化应激及临床结局的影响:双盲随机安慰剂对照临床试验研究方案

The effects of L-carnitine supplementation on inflammatory factors, oxidative stress, and clinical outcomes in patients with sepsis admitted to the intensive care unit (ICU): study protocol for a double blind, randomized, placebo-controlled clinical trial.
PubMed 文献 · Trials · 2022-02-22

本研究为双盲随机安慰剂对照临床试验方案,拟纳入伊朗伊斯法罕Al-Zahra医院60例20至65岁脓毒症患者,干预组(n=30)每日服用左卡尼汀3000 mg共7天,对照组(n=30)服用同剂量同疗程安慰剂,均加常规治疗。基线和终点评估炎症标志物、氧化应激状态及临床变量,并在干预开始后28天内评估死亡率。

要点

  • 拟纳入60例ICU脓毒症患者,随机分为左卡尼汀3000 mg/日组与安慰剂组,疗程7天。
  • 主要观察炎症因子(CRP、ESR)、氧化应激(TOS、TAC)及28天死亡率。
  • 基线评估APACHE II、SOFA、qSOFA及NUTRIC评分。

核心结论

  • 因左卡尼汀具有抗炎和抗氧化特性,每日3000 mg高剂量补充可能减轻脓毒症危重患者的炎症和氧化应激并改善后续死亡率。

研究设计与样本

  • 双盲、随机、安慰剂对照临床试验方案,采用区组随机化,拟纳入60例来自伊朗伊斯法罕Al-Zahra医院的20至65岁脓毒症患者。
  • 干预组(n=30)每日服用3粒左卡尼汀胶囊(每粒1000 mg,合计3000 mg/日)共7天,对照组(n=30)服用同剂量同疗程安慰剂,两组均加常规治疗。
  • 基线和终点评估炎症标志物(CRP、ESR)、氧化应激状态(TOS、TAC)及临床变量,干预开始后28天内评估死亡率。

关键数值与推荐

  • 干预组左卡尼汀剂量为每粒1000 mg、每日3粒、合计3000 mg/日,疗程7天。
  • 基线评估APACHE II、SOFA、qSOFA及NUTRIC评分。
  • 炎症标志物包括CRP和ESR,氧化应激指标包括TOS和TAC。
  • 死亡率评估时间为干预开始后28天内。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis is a common cause for admission to the intensive care unit (ICU), and its incidence has been increasing. It is associated with a significant increase in serum inflammatory biomarkers such as C-reactive protein (CRP) and cytokines such as interleukin 1 (IL-1), IL-6, and tumor necrosis factor (TNF). Sepsis is also associated with pathophysiological changes that include fluid accumulation in the lungs, eventually leading to acute respiratory distress syndrome (ARDS), tissue edema, hypotension, and acute kidney injury (AKI). Conventional therapies include antibiotics, but these may have important adverse effects, so novel therapeutic approaches are required. In animal studies, L-carnitine improves antioxidant status, and in some clinical trials, it has been shown to reduce inflammation. It has also been shown to improve respiratory distress and help maintain coenzyme A homeostasis, metabolic flexibility, promoting the normal function of the tricarboxylic acid (TCA) cycle, and oxidation of fatty acids by peroxisomes. We aim to determine the effects of very high doses of L-carnitine on inflammatory factors, oxidative stress, and clinical outcomes of patients with sepsis in ICU. METHOD AND DESIGN: In this double-blind, randomized controlled clinical trial, we will use block randomization of 60 patients with sepsis, aged between 20 and 65 years from Al-Zahra Hospital, Isfahan, Iran. The intervention group (n = 30) will receive three capsules of L-carnitine (each capsule contains 1000 mg L-carnitine; totally 3000 mg/day) for 7 days, and a control group (n = 30) will receive a placebo with the same dose and for the same duration in addition to usual care. At baseline, scores for clinical and nutritional status (Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), Quick SOFA (qSOFA), and NUTRIC Score) will be assessed. At beginning and end point of the study, inflammatory markers (CRP, erythrocyte sedimentation rate (ESR)), oxidative stress status (total oxidative stress (TOS), total antioxidant capacity (TAC)), and clinical variables will be evaluated also. The mortality rate will be assessed within 28 days of the beginning of the intervention. DISCUSSION: Because of the anti-inflammatory and antioxidant properties of L-carnitine, it is possible that using a high dose of 3000 mg daily of this nutritional supplement may reduce inflammation and oxidative stress and improve subsequent mortality of critically ill patients with sepsis. TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20201129049534N1 . Registered on 2 May 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Keshani M, Alikiaii B, Askari G, et al. The effects of L-carnitine supplementation on inflammatory factors, oxidative stress, and clinical outcomes in patients with sepsis admitted to the intensive care unit (ICU): study protocol for a double blind, randomized, placebo-controlled clinical trial. Trials. 2022. PMID: 35193654. doi:10.1186/s13063-022-06077-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。